OK. please enter.
Basgeen Li
7/24/2007

IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1-5. (cancelled)

6. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C ~~virus~~ viral replication in an individual comprising the step of administering to an individual a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

7. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C viral replication ~~virus~~ in cells, cell culture, or cell lysates comprising the step of administering a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said

agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase in the cells or cell culture, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

8-9. (cancelled)

10. (currently amended) ~~A method for treating Hepatitis C virus infection and/or diseases associated with HCV infection in an~~ The method according to Claim 6, wherein said individual ~~who~~ fails to respond to interferon therapy~~, said method comprising the step of administering a pharmaceutically effective amount of an agent which activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or which activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-~~

~~[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid~~.

11. (cancelled)

12. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination includes (i) a selenium salt and (ii) all-trans-retinoic acid, 9-cis retinoic acid, or 13-cis retinoic acid.

13. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes alpha interferon or pegylated alpha interferon.

14. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes ribavirin.

15-35. (cancelled)

36. (previously presented) The method according to Claim 12, wherein said combination further includes alpha interferon or pegylated interferon.

37. (previously presented) The method according to Claim 12, wherein said combination further includes ribavirin.

38. (previously presented) The method according to Claim 13, wherein said combination further includes ribavirin.

39. (previously presented) The method according to Claim 36, wherein said combination further includes ribavirin.

IN THE CLAIMS

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1-5. (cancelled)

6. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C ~~virus~~ viral replication in an individual comprising the step of administering to an individual a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

7. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C viral replication ~~virus~~ in cells, cell culture, or cell lysates comprising the step of administering a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said

agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase in the cells or cell culture, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

8-9. (cancelled)

10. (currently amended) ~~A method for treating Hepatitis C virus infection and/or diseases associated with HCV infection in an~~ The method according to Claim 6, wherein said individual ~~who~~ fails to respond to interferon therapy~~, said method comprising the step of administering a pharmaceutically effective amount of an agent which activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or which activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-~~

~~[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid~~.

11. (cancelled)

12. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination includes (i) a selenium salt and (ii) all-trans-retinoic acid, 9-cis retinoic acid, or 13-cis retinoic acid.

13. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes alpha interferon or pegylated alpha interferon.

14. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes ribavirin.

15-35. (cancelled)

36. (previously presented) The method according to Claim 12, wherein said combination further includes alpha interferon or pegylated interferon.

37. (previously presented) The method according to Claim 12, wherein said combination further includes ribavirin.

38. (previously presented) The method according to Claim 13, wherein said combination further includes ribavirin.

39. (previously presented) The method according to Claim 36, wherein said combination further includes ribavirin.

IN THE CLAIMS

OK. please enter the amendment
BL; Aug 28, 2007

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~strikethrough~~ and additions by underlining)

This listing of claims will replace all prior versions and listings of the claims in the application.

Listing of Claims:

1-5. (cancelled)

6. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C ~~virus~~ viral replication in an individual comprising the step of administering to an individual a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

7. (currently amended) A method for ~~regulating the production of~~ inhibiting or downregulating Hepatitis C viral replication ~~virus~~ in cells, cell culture, or cell lysates comprising the step of administering a pharmaceutically effective amount of an agent wherein said agent activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or wherein said

agent activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase in the cells or cell culture, and wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9-cis retinoic acid, salts of 9-cis retinoic acid, C1 - C10 alkyl esters of 9-cis retinoic acid, salts of C1 - C10 alkyl esters of 9-cis retinoic acid, C1 - C10 alkyl amides of 9-cis retinoic acid, salts of C1 - C10 alkyl amides of 9-cis retinoic acid, 13-cis retinoic acid, salts of 13-cis retinoic acid, C1 - C10 alkyl esters of 13-cis retinoic acid, salts of C1 - C10 alkyl esters of 13-cis retinoic acid, C1 - C10 alkyl amides of 13-cis retinoic acid, salts of C1 - C10 alkyl amides of 13-cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N-(4-hydroxyphenyl) retinamide (4-HPR), 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437; AHPN), all-trans-retinoic acid, C1 - C10 esters and amides of all-trans-retinoic acid, paraquat, 4-[E-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid, 4-hydroxyphenylretinamide, and 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid.

8-9. (cancelled)

10. (currently amended) ~~A method for treating Hepatitis C virus infection and/or diseases associated with HCV infection in an~~ The method according to Claim 6, wherein said individual ~~who~~ fails to respond to interferon therapy~~, said method comprising the step of administering a pharmaceutically effective amount of an agent which activates the activity of said human cellular protein gastrointestinal glutathione peroxidase or which activates or stimulates the production of said human cellular protein gastrointestinal glutathione peroxidase, wherein said agent is a combination of (i) selenium, or a selenium salt, and (ii) a retinoid selected from the group of: 9 cis retinoic acid, salts of 9 cis retinoic acid, C1 C10 alkyl esters of 9 cis retinoic acid, salts of C1 C10 alkyl esters of 9 cis retinoic acid, C1 C10 alkyl amides of 9 cis retinoic acid, salts of C1 C10 alkyl amides of 9 cis retinoic acid, 13 cis retinoic acid, salts of 13 cis retinoic acid, C1 C10 alkyl esters of 13 cis retinoic acid, salts of C1 C10 alkyl esters of 13 cis retinoic acid, C1 C10 alkyl amides of 13 cis retinoic acid, salts of C1 C10 alkyl amides of 13 cis retinoic acid, retinol, retinoic acid adlehyde, etretinate, N (4 hydroxyphenyl) retinamide (4 HPR), 6 [3 (1 adamantyl) 4 hydroxyphenyl] 2 naphthalene carboxylic acid (CD437; AHPN), all trans retinoic acid, C1 C10 esters and amides of all trans retinoic acid, paraquat, 4 [E 2 (5,6,7,8 tetrahydro 5,5,8,8 tetramethyl 2 naphthalenyl) 1 propenyl]benzoic acid, 4 hydroxyphenylretinamide, and 4~~

~~[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid~~.

11. (cancelled)

12. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination includes (i) a selenium salt and (ii) all-trans-retinoic acid, 9-cis retinoic acid, or 13-cis retinoic acid.

13. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes alpha interferon or pegylated alpha interferon.

14. (currently amended) The method according to any one of Claims 6, 7, or 10 ~~4-10~~, wherein said combination further includes ribavirin.

15-35. (cancelled)

36. (previously presented) The method according to Claim 12, wherein said combination further includes alpha interferon or pegylated interferon.

37. (previously presented) The method according to Claim 12, wherein said combination further includes ribavirin.

38. (previously presented) The method according to Claim 13, wherein said combination further includes ribavirin.

39. (previously presented) The method according to Claim 36, wherein said combination further includes ribavirin.